Search

Your search keyword '"Imprialos K."' showing total 3 results
Start Over Author "Imprialos K." Journal revista clinica espanola
3 results on '"Imprialos K."'

3. Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic.

Author

Patoulias D, Boulmpou A, Imprialos K, Stavropoulos K, Papadopoulos C, and Doumas M

Subjects
Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor agonists, Humans, Hypoglycemic Agents adverse effects, Pandemics, COVID-19, Cardiovascular Diseases epidemiology, Cardiovascular Diseases etiology, Diabetes Mellitus, Type 2 chemically induced, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 drug therapy, Respiratory Distress Syndrome drug therapy
Abstract

Patients with type 2 diabetes mellitus (T2DM) are at increased risk for severe coronavirus disease 2019 (COVID-19) and related mortality. Glucagon-like peptide-1 receptor agonists (GLP-1-RAs) have significant cardiovascular and renal benefits for patients with T2DM and related comorbidities. Their anti-inflammatory properties could be beneficial in these patients. This work provides less-biased estimates regarding the risk for respiratory tract infections and acute respiratory distress syndrome by performing the first significant meta-analysis of cardiovascular outcome trials in the literature. Notably, GLP-1-RAs do not seem to increase the risk for respiratory tract infection, pneumonia, or acute respiratory distress syndrome in patients with T2DM and cardiovascular comorbidities., (Copyright © 2021 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results